AN2 Therapeutics, Inc. 10-Q filing
Filed 2026-05-11 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-216755
- Form type
- 10-Q
- CIK
- 0001880438
- Primary document
- https://www.sec.gov/Archives/edgar/data/1880438/000119312526216755/antx-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for AN2 Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-10.6M | - | - |
| Net Income | $-10.0M | - | - |
| Eps Basic | -0.29 | - | - |
| Eps Diluted | -0.29 | - | - |
| Cash And Equivalents | $53.5M | - | - |
| Total Assets | $87.5M | - | - |
| Total Liabilities | $5.7M | - | - |
| Shareholders Equity | $81.8M | - | - |
| Operating Cash Flow | $-12.1M | - | - |